PAveMenT phase Ib trial (NCT04360941) investigated palbociclib/ avelumab combination in patients with androgen receptor-positive (AR +) TNBC(n = 12) and ER + /HER2- advanced BC(n = 2) [36]. This evidence concerns the gene AR and breast cancer.